# Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes

> **NCT01822548** · PHASE3 · COMPLETED · sponsor: **Azienda Ospedaliero-Universitaria di Parma** · enrollment: 64 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Vildagliptin
- **DRUG:** Glibenclamide
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01822548
- **Lead sponsor:** Azienda Ospedaliero-Universitaria di Parma
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-12
- **Final completion:** 2015-01
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01822548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01822548, "Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01822548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*